Article Text

Download PDFPDF
Adjuvant Chemotherapy With External BeamRadiation Therapy for High-Grade, Node-Positive Endometrial Cancer
  1. Larissa J. Lee, MD*,,
  2. Paula Bu, AB*,
  3. Colleen Feltmate, MD, and
  4. Akila N. Viswanathan, MD, MPH*,
  1. *Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute;
  2. Harvard Medical School; and
  3. Department of Gynecologic Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, MA.
  1. Address correspondence and reprint requests to Larissa J. Lee, MD, Brigham Women’s Hospital, Department of Radiation Oncology,75 Francis St, ASB1-L2, Boston, MA.E-mail: llee{at}


Objective The objective of this study was to evaluate clinical outcomes including disease-free survival (DFS) and overall survival (OS) for women with node-positive, high-grade adenocarcinoma of the uterus.

Methods Database review identified 73 patients with International Federation of Gynecology and Obstetrics stage IIIC 1/2 grade 3 endometrial cancer diagnosed from 1995 to 2009. Study inclusion required total abdominal hysterectomy/bilateral salpingo-oophorectomy and negative chest imaging. Histologic subtypes were endometrioid (22, 30%), papillary serous (20, 27%), clear cell (9, 12%), mixed (21, 29%), and undifferentiated (1, 1%). Adjuvant treatment was chemotherapy with external beam radiation therapy (EBRT) in 55 patients (75%), EBRT alone in 14 (19%), chemotherapy in 2 (3%), and no adjuvant therapy in 2 (3%).

Results With a median follow-up of 50 months, DFS/OS rates at 5 years were 44%/53%, respectively. Intraperitoneal relapse was more common in patients with positive cytology (30% vs 6%, P = 0.02) and nonendometrioid histology (16% vs 4%, P = 0.3). By histologic subtype, 5-year DFS/OS rates were 59%/82% for grade 3 endometrioid, 25%/30% for serous, 22%/17% for clear cell, and 50%/51% for mixed histology (P = 0.1/P < 0.001). The 5-year DFS/OS rates were 56%/68% for those who received both chemotherapy and EBRT. Among patients treated with adjuvant EBRT, pelvic control was 93%.

Conclusions For node-positive, high-grade endometrial cancer, patients with endometrioid and mixed histologic subtypes had better clinical outcomes than did those with serous and clear cell cancers. Distinct patterns of relapse were observed with a greater risk of intraperitoneal failure for nonendometrioid histologic subtypes. Future studies are needed to define the optimal chemotherapy regimen and radiation fields.

  • Stage IIIC endometrial cancer
  • Node-positive endometrial cancer
  • High-grade endometrial cancer
  • Radiation therapy
  • Chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.